LeMaitre Vascular (LMAT) 10-Q 6 Nov 14 2014 Q3 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	9 Months Ended
	Sep. 30, 2014	Oct. 30, 2014
Document And Entity Information [Abstract]	'	'
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	30-Sep-14	'
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q3	'
Trading Symbol	'LMAT	'
Entity Registrant Name	'LEMAITRE VASCULAR INC	'
Entity Central Index Key	'0001158895	'
Current Fiscal Year End Date	'--12-31	'
Entity Filer Category	'Smaller Reporting Company	'
Entity Common Stock, Shares Outstanding	'	17,371,225

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Current assets:	'	'
Cash and cash equivalents	$18,354	$14,711
Accounts receivable, net of allowances of $243 at September 30, 2014 and $263 at December 31, 2013	10,590	10,590
Inventory	16,925	13,255
Prepaid expenses and other current assets	3,565	3,169
Total current assets	49,434	41,725
Property and equipment, net	7,196	5,810
Goodwill	17,441	15,031
Other intangibles, net	7,635	6,144
Deferred tax assets	1,620	1,615
Other assets	174	167
Total assets	83,500	70,492
Current liabilities:	'	'
Accounts payable	1,021	1,235
Accrued expenses	8,670	7,993
Acquisition-related obligations	2,890	992
Total current liabilities	12,581	10,220
Deferred tax liabilities	3,400	3,461
Other long-term liabilities	400	249
Total liabilities	16,381	13,930
Stockholders' equity:	'	'
Preferred stock, $0.01 par value; authorized 3,000,000 shares; none outstanding	0	0
Common stock, $0.01 par value; authorized 37,000,000 shares; issued 18,778,436 shares at September 30, 2014, and 16,959,330 shares at December 31, 2013	188	170
Additional paid-in capital	75,480	65,354
Retained earnings (accumulated deficit)	1,332	-667
Accumulated other comprehensive loss	-1,628	-253
Treasury stock, at cost; 1,407,211 shares at September 30, 2014, and 1,380,119 shares at December 31, 2013	-8,253	-8,042
Total stockholders' equity	67,119	56,562
Total liabilities and stockholders' equity	$83,500	$70,492

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parenthetical) (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Thousands, except Share data, unless otherwise specified
Statement of Financial Position [Abstract]	'	'
Accounts receivable, allowances	$243	$263
Preferred stock, par value	$0.01	$0.01
Preferred stock, shares authorized	3,000,000	3,000,000
Preferred stock, shares outstanding	0	0
Common stock, par value	$0.01	$0.01
Common stock, shares authorized	37,000,000	37,000,000
Common stock, shares issued	18,778,436	16,959,330
Treasury stock, at cost	1,407,211	1,380,119

Consolidated_Statements_of_Ope

Consolidated Statements of Operations (USD $)	3 Months Ended		9 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Income Statement [Abstract]	'	'	'	'
Net sales	$17,501	$15,300	$52,416	$46,633
Cost of sales	5,498	4,584	16,813	13,474
Gross profit	12,003	10,716	35,603	33,159
Sales and marketing	5,091	5,205	16,857	16,278
General and administrative	3,765	3,282	10,376	9,231
Research and development	1,109	1,300	3,590	3,841
Medical device excise tax	178	153	518	463
Restructuring charges	8	'	500	'
Impairment charges	'	'	161	'
Total operating expenses	10,151	9,940	32,002	29,813
Income from operations	1,852	776	3,601	3,346
Other income (expense):	'	'	'	'
Interest income	1	1	2	4
Interest expense	-6	-6	-6	-18
Foreign currency gain (loss)	52	14	30	-102
Income before income taxes	1,899	785	3,627	3,230
Provision for income taxes	965	64	1,628	774
Net income	$934	$721	$1,999	$2,456
Earnings per share of common stock:	'	'	'	'
Basic	$0.05	$0.05	$0.12	$0.16
Diluted	$0.05	$0.05	$0.12	$0.16
Weighted-average shares outstanding:	'	'	'	'
Basic	17,348	15,339	16,358	15,262
Diluted	17,709	15,780	16,772	15,707
Cash dividends declared per common share	$0.04	$0.03	$0.11	$0.09

Consolidated_Statements_of_Com

Consolidated Statements of Comprehensive Income (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]	'	'	'	'
Net income	$934	$721	$1,999	$2,456
Other comprehensive income:	'	'	'	'
Foreign currency translation adjustment, net	-1,378	310	-1,375	90
Total other comprehensive income (loss)	-1,378	310	-1,375	90
Comprehensive income (loss)	($444)	$1,031	$624	$2,546

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013
Operating activities	'	'
Net income	$1,999	$2,456
Adjustments to reconcile net income to net cash provided by (used in) operating activities:	'	'
Depreciation and amortization	2,422	1,974
Stock-based compensation	982	967
Fair value adjustments to contingent considerations	138	'
Impairment charges	161	'
Provision (recovery) of doubtful accounts	31	-51
Provision for inventory write-downs	508	415
Excess tax benefits from stock-based compensation awards	-28	'
Loss on disposal of property and equipment	4	37
Provision for deferred income taxes	'	13
Foreign currency transaction loss	2	83
Changes in operating assets and liabilities:	'	'
Accounts receivable	-194	63
Inventory	-2,488	-1,943
Prepaid expenses and other assets	-403	-255
Accounts payable and other liabilities	-304	273
Net cash provided by operating activities	2,830	4,032
Investing activities	'	'
Purchases of property and equipment	-774	-2,438
Payments related to acquisitions, net of cash acquired	-5,577	-3,291
Purchase of intellectual property	-9	-141
Net cash used in investing activities	-6,360	-5,870
Financing activities	'	'
Payments of long-term debt	-1,133	'
Payment of deferred acquisition consideration	-366	'
Proceeds from issuance of common stock	10,834	699
Purchase of treasury stock	-211	-334
Common stock cash dividend paid	-1,700	-1,374
Excess tax benefits from stock-based compensation awards	28	'
Net cash provided by (used in) financing activities	7,452	-1,009
Effect of exchange rate changes on cash and cash equivalents	-279	25
Net increase (decrease) in cash and cash equivalents	3,643	-2,822
Cash and cash equivalents at beginning of period	14,711	16,448
Cash and cash equivalents at end of period	$18,354	$13,626

Organization_and_Basis_for_Pre

Organization and Basis for Presentation	9 Months Ended
	Sep. 30, 2014
Accounting Policies [Abstract]	'
Organization and Basis for Presentation	'
	1	Organization and Basis for Presentation
	Description of Business
	Unless the context requires otherwise, references to LeMaitre Vascular, we, our, and us refer to LeMaitre Vascular, Inc. and our subsidiaries. We develop, manufacture, and market medical devices and implants used primarily in the field of vascular surgery. We operate in a single segment in which our principal product lines include the following: valvulotomes, balloon catheters, carotid shunts, biologic patches, biologic grafts, radiopaque marking tape, anastomotic clips, remote endarterectomy devices, laparoscopic cholecystectomy devices, vascular grafts, angioscopes, and powered phlebectomy devices. Our offices are located in Burlington, Massachusetts; Mississauga, Canada; Sulzbach, Germany; Milan, Italy; Madrid, Spain; North Melbourne, Australia; Tokyo, Japan; and Shanghai, China.
	Basis of Presentation
	The accompanying unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (GAAP) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments, consisting only of normal, recurring adjustments considered necessary for a fair presentation of the results of these interim periods have been included. Preparing financial statements requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses. Actual results may differ from these estimates. Our estimates and assumptions, including those related to bad debts, inventories, intangible assets, sales returns and discounts, share-based compensation, and income taxes are updated as appropriate. The results for the nine months ended September 30, 2014 are not necessarily indicative of results to be expected for the entire year. The information contained in these interim financial statements should be read in conjunction with our audited consolidated financial statements as of and for the year ended December 31, 2013, including the notes thereto, included in our Form 10-K filed with the Securities and Exchange Commission (SEC).
	Consolidation
	Our consolidated financial statements include the accounts of LeMaitre Vascular and the accounts of our wholly-owned subsidiaries, LeMaitre Vascular GmbH, LeMaitre Vascular GK, Vascutech Acquisition LLC, LeMaitre Acquisition LLC, LeMaitre Vascular SAS, LeMaitre Vascular S.r.l., LeMaitre Vascular Spain SL, LeMaitre Vascular Switzerland GmbH, LeMaitre Vascular ULC, LeMaitre Vascular AS, LeMaitre Vascular Pty Ltd, and Xenotis Pty Ltd. All significant intercompany accounts and transactions have been eliminated in consolidation.
	Recent Accounting Pronouncements
	In May 2014, the Financial Accounting Standards Board issued a new accounting standard that provides for a comprehensive model to use in the accounting for revenue arising from contracts with customers that will replace most existing revenue recognition guidance in GAAP. Under this standard, revenue will be recognized to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. This standard will be effective for annual reporting periods beginning after December 15, 2016, allows for either full retrospective or modified retrospective application, and early adoption is not permitted. We are assessing the new standard and which adoption method we will apply. We have not yet determined the impact on our results of operations.

Income_Tax_Expense

Income Tax Expense	9 Months Ended
	Sep. 30, 2014
Income Tax Disclosure [Abstract]	'
Income Tax Expense	'
	2	Income Tax Expense
	As part of the process of preparing our consolidated financial statements we are required to determine our income taxes in each of the jurisdictions in which we operate. This process involves estimating our actual current tax expense together with assessing temporary differences resulting from recognition of items for income tax and accounting purposes. These differences result in deferred tax assets and liabilities, which are included within our consolidated balance sheet. We must then assess the likelihood that our deferred tax assets will be recovered from taxable income during the carryback period or in the future; and to the extent we believe that recovery is not more likely than not, we must establish a valuation allowance. To the extent we establish a valuation allowance or increase this allowance in a period, we must reflect this increase as an expense within the tax provision in the statement of operations. We do not provide for income taxes on undistributed earnings of foreign subsidiaries, as our intention is to permanently reinvest these earnings.
	We recognize, measure, present and disclose in our financial statements any uncertain tax positions that we have taken, or expect to take on a tax return. We operate in multiple taxing jurisdictions, both within and without the United States, and may be subject to audits from various tax authorities. Management’s judgment is required in determining our provision for income taxes, our deferred tax assets and liabilities, liabilities for uncertain tax positions, and any valuation allowance recorded against our net deferred tax assets. We will monitor the realizability of our deferred tax assets and adjust the valuation allowance accordingly.
	Our policy is to classify interest and penalties related to unrecognized tax benefits as income tax expense.
	Our 2014 income tax expense varies from the statutory rate mainly due to certain permanent items, lower statutory rates from a mix of our foreign entities, discrete items related to the reduction to uncertain tax positions due to the statute of limitation expiring and the release of a valuation allowance on certain foreign loss carryforwards. Our 2013 income tax expense varies from the statutory rate mainly due to discrete items related to a research and development tax credit earned in 2012, but enacted into law in January 2013, lower statutory rates from our foreign entities and certain permanent items.
	We have reviewed the tax positions taken, or to be taken, in our tax returns for all tax years currently open to examination by a taxing authority. As of September 30, 2014, the gross amount of unrecognized tax benefits exclusive of interest and penalties was $80,000. We remain subject to examination until the statute of limitations expires for each respective tax jurisdiction. The statute of limitations will be open with respect to these tax positions until 2024. A reconciliation of beginning and ending amount of our unrecognized tax benefits is as follows:
			2014
			(in thousands)
	Unrecognized tax benefits at the beginning of year		$	111
	Additions for tax positions of current year			44
	Additions for tax positions of prior years			—
	Reductions for tax positions of prior years			—
	Reductions for lapses of the applicable statutes of limitations			(75	)
	Unrecognized tax benefits at the end of the period		$	80
	In October 2014, the German tax authority completed an audit of our German subsidiary for the tax years 2009 through 2012. In October 2014, the French tax authority completed an audit of our French subsidiary for the tax years 2011 through 2013. There were no material changes to our income tax liability as a result of these audits. We are not currently under audit in any other tax jurisdictions. As of September 30, 2014, a summary of the tax years that remain subject to examination in our taxing jurisdictions is as follows:
	United States		2011 and forward
	Foreign		2004 and forward

Inventories

Inventories	9 Months Ended
	Sep. 30, 2014
Inventory Disclosure [Abstract]	'
Inventories	'
	3	Inventories
	Inventories consist of the following:
			September 30,		December 31,
			2014		2013
			(in thousands)
	Raw materials		$	3,921	$	3,647
	Work-in-process			3,460		2,949
	Finished products			9,544		6,659
	Total inventory		$	16,925	$	13,255
	We held inventory on consignment of $0.8 million as of September 30, 2014 and $0.7 million as of December 31, 2013.

Acquisition_and_Divestitures

Acquisition and Divestitures	9 Months Ended
	Sep. 30, 2014
Business Combinations [Abstract]	'
Acquisition and Divestitures	'
	4	Acquisition and Divestitures
	XenoSure Manufacturing and Distribution Rights
	In October 2012, we entered into an Asset Purchase Agreement (the Neovasc Agreement) with Neovasc, Inc. and its subsidiary, Neovasc Medical Inc. (collectively Neovasc) to acquire the manufacturing and distribution rights of the XenoSure biologic vascular patch. Previously, we were the exclusive distributor of the XenoSure biologic vascular patch through January 26, 2016 and held an option to purchase the manufacturing and distribution rights. Assets acquired in October 2012 include intellectual property, manufacturing know-how, and a five year non-compete agreement. Other provisions of the Neovasc Agreement include transitional assistance from Neovasc and mutual indemnification for losses arising out of or relating to certain breaches of, and misrepresentations under, the Neovasc Agreement. Additionally, we have entered into a supply agreement with Neovasc while we transition manufacturing to our Burlington facility.
	The purchase price for this acquisition was $4.6 million. We paid Neovasc $4.3 million at the closing of the acquisition. The remaining $0.3 million was paid in October 2013. We accounted for the acquisition as a business combination. We recorded $2.8 million of intangible assets and $1.8 million of goodwill. The weighted-average amortization period for the acquired intangible assets as of November 1, 2012 was 12.0 years. The goodwill will be deductible for tax purposes over 15 years.
	Clinical Instruments International, Inc.
	In July 2013, we entered into an asset purchase agreement with Clinical Instruments International, Inc. (Clinical Instruments) to acquire substantially all the assets of Clinical Instruments for $1.1 million. We paid $0.9 million at the closing and paid the remaining $0.2 million in October 2014. We accounted for the acquisition as a business combination. Assets acquired include inventory and intellectual property. We recorded $0.2 million of inventory, $0.3 million of intangible assets and $0.6 million of goodwill. The weighted-average amortization period for the acquired intangible assets as of July 31, 2013 was 5.7 years. The goodwill will be deductible for tax purposes over 15 years.
	InaVein LLC
	In August 2013, we entered into an asset purchase agreement with InaVein LLC (InaVein) to acquire substantially all the assets of InaVein for $2.5 million and potential acquisition-related contingent consideration totaling up to $1.4 million in 2014 and 2015 dependent on the sales performance of the acquired business and the timing of regulatory approval in China. We paid $2.1 million at the closing and paid the remaining $0.4 million in September 2014. We accounted for the acquisition as a business combination. Assets acquired include receivables, inventory, equipment, and intellectual property. Liabilities assumed include payables and service contracts. We recorded $0.8 million of tangible assets, $1.1 million of intangible assets, $0.7 million of goodwill, and $0.1 million of assumed liabilities. The weighted-average amortization period for the acquired intangible assets as of August 31, 2013 was 6.7 years. The goodwill will be deductible for tax purposes over 15 years. The first two milestones related to the potential acquisition-related contingent considerations were measured in August 2014. Based upon stronger than expected sales to China, we recorded an increase of $0.1 million in the contingent consideration dependent on the sales performance of the acquired business in the first year following the closing as a charge to general and administrative expense in the nine months ended September 30, 2014. The milestone related to the timing of the regulatory approval in China was not achieved. The final potential milestone payment is dependent on sales performance of the acquired business from August 2014 to August 2015. The contingent consideration liability related to the first sales performance milestone was $0.2 million as of September 30, 2014 and was paid in October 2014.
	Xenotis Pty Ltd
	In August 2014, we entered into a stock purchase agreement with the shareholders of Xenotis Pty Ltd (Xenotis) to acquire all of the capital stock of Xenotis for $6.7 million with a mechanism for a purchase price adjustment based on the net tangible assets of Xenotis at closing. Xenotis is the parent company of Bio Nova International, the manufacturer and marketer of the Omniflow II vascular graft for lower extremity bypass and AV access. We paid $5.1 million at the closing and the remaining $1.4 million is payable in August 2015. The net tangible asset purchase price adjustment is estimated at $0.2 million and is expected to be paid in the three months ending December 31, 2014. We accounted for the acquisition as a business combination. Assets acquired include receivables, inventory, equipment, a building, and intellectual property. Liabilities assumed include payables and debt.
	The following table summarizes the fair value of the assets acquired and liabilities assumed at the date of the acquisition:
			Allocated
			Fair Value
			(in thousands)
	Current assets		$	2,110
	Property and equipment, net			2,054
	Intangible assets			1,794
	Goodwill			2,482
	Total assets acquired			8,440
	Total liabilities assumed			(1,731	)
	Purchase price		$	6,709
	Total liabilities assumed of $1.7 million include $1.1 million of assumed debt, which we paid in full in August 2014. The purchase accounting remains in process as we determine the final net tangible asset adjustment. If the amount varies from the estimate, we will adjust the goodwill balance accordingly.
	The goodwill of $2.5 million will not be deductible for tax purposes. In addition, we acquired deferred tax assets of $2.4 million which consist primarily of net operating loss carry-forwards and capital loss carry-forwards. We recorded a full valuation allowance on these deferred tax assets.
	The following table reflects the allocation of the acquired intangible assets and related estimated useful lives:
						Weighted
			Allocated			Average
			Fair Value			Useful Life
			(in thousands)
	Non-compete agreement		$	135			5.0 years
	Tradename			142			7.0 years
	Technology			1,465			7.0 years
	Customer relationships			52			7.0 years
	Total intangible assets		$	1,794
	In September 2014, we entered into definitive agreements with five former Xenotis European based distributors to terminate their distribution of our Omniflow II vascular grafts for $1.2 million. We will pay approximately $1.2 million during the three months ending December 31, 2014 with the remainder due in 2015. We recorded $0.4 million of inventory and $0.8 million of intangible assets. We allocated the payment to the tangible and intangible assets acquired based on the estimated fair value of each of these elements to the transactions. The weighted-average amortization period for the acquired intangible assets is 5.0 years.
	AngioScope
	In September 2014, we entered into an asset purchase agreement with Applied Medical Resource Corporation (Applied Medical) to acquire substantially all the assets related to Applied Medical’s angioscope product line for $0.4 million. We paid $0.3 million at closing and the remaining $0.1 million is payable in December 2015. We accounted for the acquisition as a business combination. Assets acquired include inventory, property and equipment, and intellectual property.
	The following table summarizes the fair value of the assets acquired and liabilities assumed at the date of the acquisition:
			Allocated
			Fair Value
			(in thousands)
	Inventory		$	26
	Property and equipment, net			38
	Intangible assets			276
	Goodwill			80
	Total assets acquired			420
	Total liabilities assumed			—
	Purchase price		$	420
	The goodwill of $0.1 million will be deductible for tax purposes over 15 years.
	The following table reflects the allocation of the acquired intangible assets and related estimated useful lives:
						Weighted
			Allocated			Average
			Fair Value			Useful Life
			(in thousands)
	Non-compete agreement		$	3			2.0 years
	Tradename			28			7.0 years
	Technology			163			7.0 years
	Customer relationships			82			9.0 years
	Total intangible assets		$	276
	Our acquisitions have historically been made at prices above the fair value of the acquired identifiable assets, resulting in goodwill, due to expectations of synergies that will be realized by combining businesses. These synergies include the use of our existing sales channel to expand sales of the acquired businesses’ products, consolidation of manufacturing facilities, and the leveraging of our existing administrative infrastructure.
	The fair market valuations associated with these transactions fall within Level 3 of the fair value hierarchy, due to the use of significant unobservable inputs to determine fair value. The fair value measurements were calculated using unobservable inputs, primarily using the income approach, specifically the discounted cash flow method. The amount and timing of future cash flows within our analysis was based on our due diligence models, most recent operational budgets, long range strategic plans and other estimates.

Goodwill_and_Other_Intangibles

Goodwill and Other Intangibles	9 Months Ended
	Sep. 30, 2014
Goodwill and Intangible Assets Disclosure [Abstract]	'
Goodwill and Other Intangibles	'
	5	Goodwill and Other Intangibles
	Goodwill consists of the following:
			(in thousands)
	Balance at beginning of year		$	15,031
	Additions for acquisitions			2,562
	Effects of currency exchange			(152	)
	Balance at September 30, 2014		$	17,441
	Other intangibles consist of the following:
			September 30, 2014							December 31, 2013
			Gross					Net		Gross				Net
			Carrying			Accumulated		Carrying		Carrying		Accumulated		Carrying
			Value			Amortization		Value		Value		Amortization		Value
			(in thousands)
	Patents		$	7,225		$	2,589	$	4,636	$	5,679	$	1,932	$	3,747
	Trademarks and technology licenses			1,575			1,044		531		1,414		935		479
	Customer relationships			3,675			1,683		1,992		2,835		1,441		1,394
	Other intangible assets			1,095			619		476		971		447		524
	Total identifiable intangible assets		$	13,570		$	5,935	$	7,635	$	10,899	$	4,755	$	6,144
	These intangible assets are being amortized over their useful lives ranging from 1 to 13 years. The weighted-average amortization period for these intangibles as of September 30, 2014 is 7.8 years. Amortization expense is included in general and administrative expense and is as follows:
			Three months ended September 30,					Nine months ended September 30,
			2014			2013		2014		2013
			(in thousands)
	Amortization expense		$	359		$	323	$	1,098	$	857
	Estimated amortization expense for the remainder of 2014 and each of the five succeeding fiscal years is as follows:
			2014			2015		2016		2017		2018		2019
			(in thousands)
	Amortization expense		$	435		$	1,434	$	1,294	$	1,049	$	934	$	773
	During the three months ended June 30, 2014, we recognized an impairment charge of $0.2 million related to trademarks and technology upon the terminaton of our non-occlusive modeling catheter product line. Additionally, we recognized a $0.3 million charge to cost of sales related to the non-occlusive modeling catheter inventory.

Accrued_Expenses

Accrued Expenses	9 Months Ended
	Sep. 30, 2014
Text Block [Abstract]	'
Accrued Expenses	'
	6	Accrued Expenses
	Accrued expenses consist of the following:
			September 30, 2014		December 31, 2013
			(in thousands)
	Compensation and related taxes		$	4,519	$	4,710
	Income and other taxes			1,606		885
	Professional fees			508		428
	Restructuring charges			48		—
	Other			1,894		1,970
	Total		$	8,575	$	7,993

Restructuring

Restructuring	9 Months Ended
	Sep. 30, 2014
Restructuring and Related Activities [Abstract]	'
Restructuring	'
	7	Restructuring
	In February 2014, we committed to a plan intended to improve operational efficiencies, which included a reduction in force of approximately 10% of our workforce and other cost-cutting measures, including the transfer of our recently acquired Clinical Instruments manufacturing to our Burlington headquarters and corresponding closure of our Southbridge manufacturing facility. As a result, we recorded approximately $0.4 million of severance related restructuring expense for the three months ended March 31, 2014.
	In April 2014, we committed to an additional reduction in force of approximately 7 employees. As a result, we recorded approximately $0.1 million of severance related restructuring expense for the three months ended June 30, 2014.
	The components of our restructuring charges are as follows:
			Three months ended		Nine months ended
			September 30,		September 30,
			2014		2014
			(in thousands)
	Severance		$	—	$	473
	Other			8		27
	Total		$	8	$	500
	Activity related to accrued restructuring costs is as follows:
			Nine months ended
			September 30, 2014
			(in thousands)
	Balance at beginning of year		$	—
	Plus:
	Current year restructuring costs			500
	Less:
	Payment of employee severance costs			425
	Payment of other expenses			27
	Balance at end of period		$	48

Commitments_and_Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2014
Commitments and Contingencies Disclosure [Abstract]	'
Commitments and Contingencies	'
	8	Commitments and Contingencies
	Purchase Commitments
	As of September 30, 2014, as part of our normal course of business, we have purchase commitments to purchase $3.1 million of inventory through 2016.

Segment_and_EnterpriseWide_Dis

Segment and Enterprise-Wide Disclosures	9 Months Ended
	Sep. 30, 2014
Segment Reporting [Abstract]	'
Segment and Enterprise-Wide Disclosures	'
	9	Segment and Enterprise-Wide Disclosures
	The FASB establishes standards for reporting information regarding operating segments in financial statements. Operating segments are identified as components of an enterprise about which separate, discrete financial information is evaluated by the chief operating decision-maker in making decisions on how to allocate resources and assess performance. We view our operations and manage our business as one operating segment. No discrete operating information is prepared by us except for product sales by product line and by legal entity for local reporting purposes.
	Most of our revenues were generated in the United States, Germany, Japan, Canada, and other European countries, and substantially all of our assets are located in the United States. Net sales to unaffiliated customers by country were as follows:
			Three months ended				Nine months ended
			September 30, 2014				September 30, 2014
			2014		2013		2014		2013
			(in thousands)
	United States		$	10,605	$	9,506	$	31,221	$	28,820
	Germany			1,789		1,805		5,551		5,166
	Japan			581		609		1,704		1,779
	Other countries			4,526		3,380		13,940		10,868
	Net Sales		$	17,501	$	15,300	$	52,416	$	46,633

Sharebased_Compensation

Share-based Compensation	9 Months Ended
	Sep. 30, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Share-based Compensation	'
	10	Share-based Compensation
	Our 2006 Stock Option and Incentive Plan allows for granting of incentive stock options, non-qualified stock options, stock appreciation rights, restricted stock units, unrestricted stock awards, and deferred stock awards to our officers, employees, directors, and consultants.
	The components of share-based compensation expense were as follows:
			Three months ended						Nine months ended
			September 30,						September 30,
			2014			2013			2014		2013
			(in thousands)
	Stock option awards		$	294		$	252		$	687	$	596
	Restricted stock units			145			160			295		371
	Total share-based compensation		$	439		$	412		$	982	$	967
	We have computed the fair values of employee stock options for option grants issued during the nine months ended September 30, 2014 and 2013 using the Black-Scholes option model with the following assumptions:
			2014			2013
	Dividend yield			1.8	%		1.8	%
	Volatility			45.2	%		57.9	%
	Risk-free interest rate			2	%		1.6	%
	Weighted average expected option term (in years)			5.5			5.6
	Weighted average fair value per share of options granted		$	2.81		$	3
	The weighted-average fair value per share of restricted stock unit grants issued for the nine months ended September 30, 2014 was $7.87. The weighted-average fair value per share of restricted stock unit grants issued for the nine months ended September 30, 2013 was $6.67.
	We issued approximately 175,000 and 255,000 shares of common stock following the exercise or vesting of underlying stock options or restricted stock units in the nine months ended September 30, 2014 and 2013, respectively.

Net_Income_per_Share

Net Income per Share	9 Months Ended
	Sep. 30, 2014
Earnings Per Share [Abstract]	'
Net Income per Share	'
	11	Net Income per Share
	The computation of basic and diluted net income per share was as follows:
			Three months ended				Nine months ended
			September 30,				September 30,
			2014		2013		2014		2013
			(in thousands, except per share data)
	Basic:
	Net income available for common stockholders		$	934	$	721	$	1,999	$	2,456
	Weighted average shares outstanding			17,348		15,339		16,358		15,262
	Basic earnings per share		$	0.05	$	0.05	$	0.12	$	0.16
	Diluted:
	Net income available for common stockholders		$	934	$	721	$	1,999	$	2,456
	Weighted-average shares outstanding			17,348		15,339		16,358		15,262
	Common stock equivalents, if diluted			361		441		414		445
	Shares used in computing diluted earnings per common share			17,709		15,780		16,772		15,707
	Diluted earnings per share		$	0.05	$	0.05	$	0.12	$	0.16
	Shares excluded in computing diluted earnings per share as those shares would be anti-dilutive			356		395		228		438

Stockholders_Equity

Stockholders' Equity	9 Months Ended
	Sep. 30, 2014
Equity [Abstract]	'
Stockholders' Equity	'
	12	Stockholders’ Equity
	Authorized Shares
	On June 14, 2012, our stockholders approved an amendment (Charter Amendment) to our Second Amended and Restated Certificate of Incorporation to reduce the number of authorized shares of common stock from 100,000,000 to 37,000,000 shares and of undesignated preferred stock from 5,000,000 to 3,000,000 shares. The Charter Amendment was previously approved by our Board of Directors on April 12, 2012, subject to approval by our stockholders. The Charter Amendment was filed with the Secretary of State of the State of Delaware on June 14, 2012.
	Share Offering
	On June 4, 2014, we issued 1,644,500 shares of our common stock, $0.01 par value per share at a price to the public of $7.00 per share less underwriting discounts. The net proceeds, after deducting the underwriting discounts and other estimated offering expenses, were approximately $10.5 million. We have deployed a portion of the net proceeds from the offering on our recent acquisitions and expect to use the remainder for general corporate purposes, including continued development of our products, working capital and capital expenditures, payments under our quarterly dividend program, deferred payments related to prior acquisitions, and to fund acquisitions.
	Dividends
	In February 2011, our Board of Directors approved a policy for the payment of quarterly cash dividends on our common stock. Future declarations of quarterly dividends and the establishment of future record and payment dates are subject to approval by our Board of Directors on a quarterly basis. The dividend activity for the periods presented is as follows:
	Record Date		Payment Date		Per Share Amount		Dividend Payment
							(in thousands)
	Fiscal Year 2014
	March 20, 2014			3-Apr-14	$	0.035	$	546
	May 22, 2014			5-Jun-14	$	0.035	$	547
	August 21, 2014			September 4, 2014	$	0.035	$	607
	Fiscal Year 2013
	March 20, 2013			3-Apr-13	$	0.03	$	457
	May 22, 2013			5-Jun-13	$	0.03	$	457
	August 21, 2013			4-Sep-13	$	0.03	$	460
	November 20, 2013			4-Dec-13	$	0.03	$	464
	On October 23, 2014, our Board of Directors approved a quarterly cash dividend on our common stock of $0.035 per share payable on December 4, 2014 to stockholders of record at the close of business on November 20, 2014, which will total approximately $0.6 million.
	Stock Repurchase Plan
	In July 2009, our Board of Directors authorized a repurchase of our common stock from time to time on the open market or in privately negotiated transactions. In November 2011, our Board of Directors increased this authorization to $10.0 million and extended the program through December 31, 2013. The timing and number of any shares repurchased were determined based on our evaluation of market conditions and other factors. Repurchases were also made under a Rule 10b5-1 plan, which would permit shares to be repurchased when we might otherwise be precluded from doing so under insider trading laws. Our last repurchases occurred during the three months ended March 31, 2013 in which we purchased approximately 15,000 shares for approximately $0.1 million. The repurchase program concluded as of December 31, 2013.

Supplemental_Cash_Flow_Informa

Supplemental Cash Flow Information	9 Months Ended
	Sep. 30, 2014
Supplemental Cash Flow Elements [Abstract]	'
Supplemental Cash Flow Information	'
	13	Supplemental Cash Flow Information
			Nine months ended
			September 30,
			2014		2013
			(in thousands)
	Cash paid for income taxes, net		$	1,276	$	755
	Common stock repurchased for RSU tax withholdings		$	211	$	246

Fair_Value_Measurements

Fair Value Measurements	9 Months Ended
	Sep. 30, 2014
Fair Value Disclosures [Abstract]	'
Fair Value Measurements	'
	14	Fair Value Measurements
	The fair value accounting guidance requires that assets and liabilities carried at fair value be classified and disclosed in one of the following three categories:
		•		Level 1 — Quoted prices in active markets for identical assets or liabilities.
		•		Level 2 — Observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data.
		•		Level 3 — Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. This includes certain pricing models, discounted cash flow methodologies and similar techniques that use significant unobservable inputs.
	As of September 30, 2014, we had cash equivalents in a money market fund that was valued using Level 1 inputs (quoted market prices for identical assets) at a fair value of $12.0 million.
	We had no Level 2 assets being measured at fair value on a recurring basis as of September 30, 2014.
	As discussed in Note 4, we have contingent liabilities related to the acquisition of InaVein LLC that are remeasured each reporting period using Level 3 techniques based on an assessment of the probability that we will be required to make such future payment. Based upon stronger than expected sales to China, we recorded an increase in the contingent consideration of $0.1 million as a charge to general and administrative expense in the nine months ended September 30, 2014. The following table provides a roll-forward of the fair value, as determined by Level 3 inputs, of the contingent consideration.
			Nine months ended
			September 30,
			2014
	Beginning balance		$	99
	Additions (reductions)			—
	Change in fair value included in earnings			138
	Ending Balance		$	237

Accumulated_Other_Comprehensiv

Accumulated Other Comprehensive Loss	9 Months Ended
	Sep. 30, 2014
Equity [Abstract]	'
Accumulated Other Comprehensive Loss	'
	15	Accumulated Other Comprehensive Loss
	Changes to our accumulated other comprehensive loss consisted of foreign currency translation for the nine months ended September 30, 2014 and 2013, respectively.
			Nine months ended
			September 30,
			2014			2013
	Beginning balance		$	(253	)	$	(433	)
	Other comprehensive income (loss) before reclassifications			(1,375	)		90
	Amounts reclassified from accumulated other comprehensive loss			—			—
	Net current period other comprehensive income (loss)			(1,375	)		90
	Ending Balance		$	(1,628	)	$	(343	)

Organization_and_Basis_for_Pre1

Organization and Basis for Presentation (Policies)	9 Months Ended
	Sep. 30, 2014
Accounting Policies [Abstract]	'
Description of Business	'
	Description of Business
	Unless the context requires otherwise, references to LeMaitre Vascular, we, our, and us refer to LeMaitre Vascular, Inc. and our subsidiaries. We develop, manufacture, and market medical devices and implants used primarily in the field of vascular surgery. We operate in a single segment in which our principal product lines include the following: valvulotomes, balloon catheters, carotid shunts, biologic patches, biologic grafts, radiopaque marking tape, anastomotic clips, remote endarterectomy devices, laparoscopic cholecystectomy devices, vascular grafts, angioscopes, and powered phlebectomy devices. Our offices are located in Burlington, Massachusetts; Mississauga, Canada; Sulzbach, Germany; Milan, Italy; Madrid, Spain; North Melbourne, Australia; Tokyo, Japan; and Shanghai, China.
Basis of Presentation	'
	Basis of Presentation
	The accompanying unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (GAAP) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments, consisting only of normal, recurring adjustments considered necessary for a fair presentation of the results of these interim periods have been included. Preparing financial statements requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses. Actual results may differ from these estimates. Our estimates and assumptions, including those related to bad debts, inventories, intangible assets, sales returns and discounts, share-based compensation, and income taxes are updated as appropriate. The results for the nine months ended September 30, 2014 are not necessarily indicative of results to be expected for the entire year. The information contained in these interim financial statements should be read in conjunction with our audited consolidated financial statements as of and for the year ended December 31, 2013, including the notes thereto, included in our Form 10-K filed with the Securities and Exchange Commission (SEC).
Consolidation	'
	Consolidation
	Our consolidated financial statements include the accounts of LeMaitre Vascular and the accounts of our wholly-owned subsidiaries, LeMaitre Vascular GmbH, LeMaitre Vascular GK, Vascutech Acquisition LLC, LeMaitre Acquisition LLC, LeMaitre Vascular SAS, LeMaitre Vascular S.r.l., LeMaitre Vascular Spain SL, LeMaitre Vascular Switzerland GmbH, LeMaitre Vascular ULC, LeMaitre Vascular AS, LeMaitre Vascular Pty Ltd, and Xenotis Pty Ltd. All significant intercompany accounts and transactions have been eliminated in consolidation.
Recent Accounting Pronouncements	'
	Recent Accounting Pronouncements
	In May 2014, the Financial Accounting Standards Board issued a new accounting standard that provides for a comprehensive model to use in the accounting for revenue arising from contracts with customers that will replace most existing revenue recognition guidance in GAAP. Under this standard, revenue will be recognized to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. This standard will be effective for annual reporting periods beginning after December 15, 2016, allows for either full retrospective or modified retrospective application, and early adoption is not permitted. We are assessing the new standard and which adoption method we will apply. We have not yet determined the impact on our results of operations.
Income Taxes	'
	As part of the process of preparing our consolidated financial statements we are required to determine our income taxes in each of the jurisdictions in which we operate. This process involves estimating our actual current tax expense together with assessing temporary differences resulting from recognition of items for income tax and accounting purposes. These differences result in deferred tax assets and liabilities, which are included within our consolidated balance sheet. We must then assess the likelihood that our deferred tax assets will be recovered from taxable income during the carryback period or in the future; and to the extent we believe that recovery is not more likely than not, we must establish a valuation allowance. To the extent we establish a valuation allowance or increase this allowance in a period, we must reflect this increase as an expense within the tax provision in the statement of operations. We do not provide for income taxes on undistributed earnings of foreign subsidiaries, as our intention is to permanently reinvest these earnings.
	Our policy is to classify interest and penalties related to unrecognized tax benefits as income tax expense.
Income Tax Uncertainties	'
	We recognize, measure, present and disclose in our financial statements any uncertain tax positions that we have taken, or expect to take on a tax return. We operate in multiple taxing jurisdictions, both within and without the United States, and may be subject to audits from various tax authorities. Management’s judgment is required in determining our provision for income taxes, our deferred tax assets and liabilities, liabilities for uncertain tax positions, and any valuation allowance recorded against our net deferred tax assets. We will monitor the realizability of our deferred tax assets and adjust the valuation allowance accordingly.
Segment Reporting	'
	The FASB establishes standards for reporting information regarding operating segments in financial statements. Operating segments are identified as components of an enterprise about which separate, discrete financial information is evaluated by the chief operating decision-maker in making decisions on how to allocate resources and assess performance. We view our operations and manage our business as one operating segment. No discrete operating information is prepared by us except for product sales by product line and by legal entity for local reporting purposes.
Fair Value Measurement	'
	The fair value accounting guidance requires that assets and liabilities carried at fair value be classified and disclosed in one of the following three categories:
		•	Level 1 — Quoted prices in active markets for identical assets or liabilities.
		•	Level 2 — Observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data.
		•	Level 3 — Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. This includes certain pricing models, discounted cash flow methodologies and similar techniques that use significant unobservable inputs.

Income_Tax_Expense_Tables

Income Tax Expense (Tables)	9 Months Ended
	Sep. 30, 2014
Income Tax Disclosure [Abstract]	'
Reconciliation of Beginning and Ending Amount of Unrecognized Tax Benefits	'
	A reconciliation of beginning and ending amount of our unrecognized tax benefits is as follows:
		2014
		(in thousands)
	Unrecognized tax benefits at the beginning of year	$	111
	Additions for tax positions of current year		44
	Additions for tax positions of prior years		—
	Reductions for tax positions of prior years		—
	Reductions for lapses of the applicable statutes of limitations		(75	)
	Unrecognized tax benefits at the end of the period	$	80
Summary of Tax Years Subject to Examination in Most Significant Tax Jurisdictions	'
	As of September 30, 2014, a summary of the tax years that remain subject to examination in our taxing jurisdictions is as follows:
	United States	2011 and forward
	Foreign	2004 and forward

Inventories_Tables

Inventories (Tables)	9 Months Ended
	Sep. 30, 2014
Inventory Disclosure [Abstract]	'
Summary of Inventories	'
	Inventories consist of the following:
		September 30,		December 31,
		2014		2013
		(in thousands)
	Raw materials	$	3,921	$	3,647
	Work-in-process		3,460		2,949
	Finished products		9,544		6,659
	Total inventory	$	16,925	$	13,255

Acquisition_and_Divestitures_T

Acquisition and Divestitures (Tables)	9 Months Ended
	Sep. 30, 2014
Xenotis Pty Ltd [Member]	'
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed	'
	The following table summarizes the fair value of the assets acquired and liabilities assumed at the date of the acquisition:
		Allocated
		Fair Value
		(in thousands)
	Current assets	$	2,110
	Property and equipment, net		2,054
	Intangible assets		1,794
	Goodwill		2,482
	Total assets acquired		8,440
	Total liabilities assumed		(1,731	)
	Purchase price	$	6,709
Acquired Intangible Assets and Related Estimated Useful Lives	'
	The following table reflects the allocation of the acquired intangible assets and related estimated useful lives:
					Weighted
		Allocated			Average
		Fair Value			Useful Life
		(in thousands)
	Non-compete agreement	$	135			5.0 years
	Tradename		142			7.0 years
	Technology		1,465			7.0 years
	Customer relationships		52			7.0 years
	Total intangible assets	$	1,794
AngioScope [Member]	'
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed	'
	The following table summarizes the fair value of the assets acquired and liabilities assumed at the date of the acquisition:
		Allocated
		Fair Value
		(in thousands)
	Inventory	$	26
	Property and equipment, net		38
	Intangible assets		276
	Goodwill		80
	Total assets acquired		420
	Total liabilities assumed		—
	Purchase price	$	420
Acquired Intangible Assets and Related Estimated Useful Lives	'
	The following table reflects the allocation of the acquired intangible assets and related estimated useful lives:
					Weighted
		Allocated			Average
		Fair Value			Useful Life
		(in thousands)
	Non-compete agreement	$	3			2.0 years
	Tradename		28			7.0 years
	Technology		163			7.0 years
	Customer relationships		82			9.0 years
	Total intangible assets	$	276

Goodwill_and_Other_Intangibles1

Goodwill and Other Intangibles (Tables)	9 Months Ended
	Sep. 30, 2014
Goodwill and Intangible Assets Disclosure [Abstract]	'
Schedule of Goodwill	'
	Goodwill consists of the following:
		(in thousands)
	Balance at beginning of year	$	15,031
	Additions for acquisitions		2,562
	Effects of currency exchange		(152	)
	Balance at September 30, 2014	$	17,441
Components of Identifiable Intangible Assets	'
	Other intangibles consist of the following:
		September 30, 2014							December 31, 2013
		Gross					Net		Gross				Net
		Carrying			Accumulated		Carrying		Carrying		Accumulated		Carrying
		Value			Amortization		Value		Value		Amortization		Value
		(in thousands)
	Patents	$	7,225		$	2,589	$	4,636	$	5,679	$	1,932	$	3,747
	Trademarks and technology licenses		1,575			1,044		531		1,414		935		479
	Customer relationships		3,675			1,683		1,992		2,835		1,441		1,394
	Other intangible assets		1,095			619		476		971		447		524
	Total identifiable intangible assets	$	13,570		$	5,935	$	7,635	$	10,899	$	4,755	$	6,144
Amortization Expense Included in General and Administrative Expense	'
	Amortization expense is included in general and administrative expense and is as follows:
		Three months ended September 30,					Nine months ended September 30,
		2014			2013		2014		2013
		(in thousands)
	Amortization expense	$	359		$	323	$	1,098	$	857
Estimated Amortization Expense for Remainder of 2014 and Each of Five Succeeding Fiscal Years	'
	Estimated amortization expense for the remainder of 2014 and each of the five succeeding fiscal years is as follows:
		2014			2015		2016		2017		2018		2019
		(in thousands)
	Amortization expense	$	435		$	1,434	$	1,294	$	1,049	$	934	$	773

Accrued_Expenses_Tables

Accrued Expenses (Tables)	9 Months Ended
	Sep. 30, 2014
Text Block [Abstract]	'
Accrued Expenses	'
	Accrued expenses consist of the following:
		September 30, 2014		December 31, 2013
		(in thousands)
	Compensation and related taxes	$	4,519	$	4,710
	Income and other taxes		1,606		885
	Professional fees		508		428
	Restructuring charges		48		—
	Other		1,894		1,970
	Total	$	8,575	$	7,993

Restructuring_Tables

Restructuring (Tables)	9 Months Ended
	Sep. 30, 2014
Restructuring and Related Activities [Abstract]	'
Components of Restructuring Charges	'
	The components of our restructuring charges are as follows:
		Three months ended		Nine months ended
		September 30,		September 30,
		2014		2014
		(in thousands)
	Severance	$	—	$	473
	Other		8		27
	Total	$	8	$	500
Activity Related to Accrued Restructuring Costs	'
	Activity related to accrued restructuring costs is as follows:
		Nine months ended
		September 30,
		2014
		(in thousands)
	Balance at beginning of year	$	—
	Plus:
	Current year restructuring costs		500
	Less:
	Payment of employee severance costs		425
	Payment of other expenses		27
	Balance at end of period	$	48

Segment_and_EnterpriseWide_Dis1

Segment and Enterprise-Wide Disclosures (Tables)	9 Months Ended
	Sep. 30, 2014
Segment Reporting [Abstract]	'
Net Sales to Unaffiliated Customers by Geography	'
	Net sales to unaffiliated customers by country were as follows:
		Three months ended				Nine months ended
		September 30, 2014				September 30, 2014
		2014		2013		2014		2013
		(in thousands)
	United States	$	10,605	$	9,506	$	31,221	$	28,820
	Germany		1,789		1,805		5,551		5,166
	Japan		581		609		1,704		1,779
	Other countries		4,526		3,380		13,940		10,868
	Net Sales	$	17,501	$	15,300	$	52,416	$	46,633

Sharebased_Compensation_Tables

Share-based Compensation (Tables)	9 Months Ended
	Sep. 30, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Share-based Compensation Expense	'
	The components of share-based compensation expense were as follows:
		Three months ended						Nine months ended
		September 30,						September 30,
		2014			2013			2014		2013
		(in thousands)
	Stock option awards	$	294		$	252		$	687	$	596
	Restricted stock units		145			160			295		371
	Total share-based compensation	$	439		$	412		$	982	$	967
Fair Values of Employee Stock Options for Option Grants Issued Valuation Assumptions Using Black-Scholes Option Model	'
	We have computed the fair values of employee stock options for option grants issued during the nine months ended September 30, 2014 and 2013 using the Black-Scholes option model with the following assumptions:
		2014			2013
	Dividend yield		1.8	%		1.8	%
	Volatility		45.2	%		57.9	%
	Risk-free interest rate		2	%		1.6	%
	Weighted average expected option term (in years)		5.5			5.6
	Weighted average fair value per share of options granted	$	2.81		$	3

Net_Income_per_Share_Tables

Net Income per Share (Tables)	9 Months Ended
	Sep. 30, 2014
Earnings Per Share [Abstract]	'
Computation of Basic and Diluted Net Income per Share	'
	The computation of basic and diluted net income per share was as follows:
		Three months ended				Nine months ended
		September 30,				September 30,
		2014		2013		2014		2013
		(in thousands, except per share data)
	Basic:
	Net income available for common stockholders	$	934	$	721	$	1,999	$	2,456
	Weighted average shares outstanding		17,348		15,339		16,358		15,262
	Basic earnings per share	$	0.05	$	0.05	$	0.12	$	0.16
	Diluted:
	Net income available for common stockholders	$	934	$	721	$	1,999	$	2,456
	Weighted-average shares outstanding		17,348		15,339		16,358		15,262
	Common stock equivalents, if diluted		361		441		414		445
	Shares used in computing diluted earnings per common share		17,709		15,780		16,772		15,707
	Diluted earnings per share	$	0.05	$	0.05	$	0.12	$	0.16
	Shares excluded in computing diluted earnings per share as those shares would be anti-dilutive		356		395		228		438

Stockholders_Equity_Tables

Stockholders' Equity (Tables)	9 Months Ended
	Sep. 30, 2014
Equity [Abstract]	'
Dividend Activity	'
	The dividend activity for the periods presented is as follows:
	Record Date	Payment Date		Per Share Amount		Dividend Payment
						(in thousands)
	Fiscal Year 2014
	March 20, 2014		3-Apr-14	$	0.035	$	546
	May 22, 2014		5-Jun-14	$	0.035	$	547
	August 21, 2014		September 4, 2014	$	0.035	$	607
	Fiscal Year 2013
	March 20, 2013		3-Apr-13	$	0.03	$	457
	May 22, 2013		5-Jun-13	$	0.03	$	457
	August 21, 2013		4-Sep-13	$	0.03	$	460
	November 20, 2013		4-Dec-13	$	0.03	$	464

Supplemental_Cash_Flow_Informa1

Supplemental Cash Flow Information (Tables)	9 Months Ended
	Sep. 30, 2014
Supplemental Cash Flow Elements [Abstract]	'
Supplemental Cash Flow Information	'
		Nine months ended
		September 30,
		2014		2013
		(in thousands)
	Cash paid for income taxes, net	$	1,276	$	755
	Common stock repurchased for RSU tax withholdings	$	211	$	246

Fair_Value_Measurements_Tables

Fair Value Measurements (Tables)	9 Months Ended
	Sep. 30, 2014
Fair Value Disclosures [Abstract]	'
Rollforward of the Fair Value as Determined by Level 3	'
	The following table provides a roll-forward of the fair value, as determined by Level 3 inputs, of the contingent consideration.
		Nine months ended
		September 30,
		2014
	Beginning balance	$	99
	Additions (reductions)		—
	Change in fair value included in earnings		138
	Ending Balance	$	237

Accumulated_Other_Comprehensiv1

Accumulated Other Comprehensive Loss (Tables)	9 Months Ended
	Sep. 30, 2014
Equity [Abstract]	'
Summary of Accumulated Other Comprehensive Loss	'
	Changes to our accumulated other comprehensive loss consisted of foreign currency translation for the nine months ended September 30, 2014 and 2013, respectively.
		Nine months ended
		September 30,
		2014			2013
	Beginning balance	$	(253	)	$	(433	)
	Other comprehensive income (loss) before reclassifications		(1,375	)		90
	Amounts reclassified from accumulated other comprehensive loss		—			—
	Net current period other comprehensive income (loss)		(1,375	)		90
	Ending Balance	$	(1,628	)	$	(343	)

Income_Tax_Expense_Additional_

Income Tax Expense - Additional Information (Detail) (USD $)	9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Dec. 31, 2013
Income Tax Disclosure [Abstract]	'	'
Unrecognized tax benefits exclusive of interest and penalties, gross	$80	$111
Statute of limitations expiration period	'Until 2024	'
Income tax examination period	'In October 2014, the German tax authority completed an audit of our German subsidiary for the tax years 2009 through 2012.	'

Income_Tax_Expense_Reconciliat

Income Tax Expense - Reconciliation of Beginning and Ending Amount of Unrecognized Tax Benefits (Detail) (USD $)	9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014
Income Tax Disclosure [Abstract]	'
Unrecognized tax benefits at the beginning of year	$111
Additions for tax positions of current year	44
Additions for tax positions of prior years	'
Reductions for tax positions of prior years	'
Reductions for lapses of the applicable statutes of limitations	-75
Unrecognized tax benefits at the end of the period	$80

Income_Tax_Expense_Summary_of_

Income Tax Expense - Summary of Tax Years Subject to Examination in Most Significant Tax Jurisdictions (Detail)	9 Months Ended
	Sep. 30, 2014
United States [Member]	'
Income Tax Examination [Line Items]	'
Income tax year under examination	'2011 and forward
Foreign [Member]	'
Income Tax Examination [Line Items]	'
Income tax year under examination	'2004 and forward

Inventories_Summary_of_Invento

Inventories - Summary of Inventories (Detail) (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Inventory Disclosure [Abstract]	'	'
Raw materials	$3,921	$3,647
Work-in-process	3,460	2,949
Finished products	9,544	6,659
Total inventory	$16,925	$13,255

Inventories_Additional_Informa

Inventories - Additional Information (Detail) (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Millions, unless otherwise specified
Inventory Disclosure [Abstract]	'	'
Inventory on consignment	$0.80	$0.70

Acquisition_and_Divestitures_A

Acquisition and Divestitures - Additional Information (Detail) (USD $)

9 Months Ended

0 Months Ended

1 Months Ended

1 Months Ended

9 Months Ended

1 Months Ended

9 Months Ended

1 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

1 Months Ended

9 Months Ended

1 Months Ended

Sep. 30, 2014

Dec. 31, 2013

Nov. 01, 2012

Oct. 31, 2012

Oct. 31, 2013

Jul. 31, 2013

Sep. 30, 2014

Sep. 30, 2014

Aug. 31, 2013

Sep. 30, 2014

Aug. 31, 2014

Sep. 30, 2014

Sep. 30, 2014

Dec. 31, 2014

Dec. 31, 2014

Sep. 30, 2014

Oct. 31, 2012

Sep. 30, 2014

Aug. 31, 2014

Sep. 30, 2014

XenoSure [Member]

XenoSure [Member]

XenoSure [Member]

Clinical Instruments [Member]

Clinical Instruments [Member]

InaVein LLC [Member]

InaVein LLC [Member]

InaVein LLC [Member]

Xenotis Pty Ltd [Member]

Xenotis Pty Ltd [Member]

Xenotis Pty Ltd [Member]

Xenotis Pty Ltd [Member]

Xenotis Pty Ltd [Member]

AngioScope [Member]

Non-compete Agreement [Member]

Non-compete Agreement [Member]

Non-compete Agreement [Member]

Non-compete Agreement [Member]

Europe [Member]

Scenario, Forecast [Member]

Scenario, Forecast [Member]

XenoSure [Member]

XenoSure [Member]

Xenotis Pty Ltd [Member]

AngioScope [Member]

Europe [Member]

Business Acquisition [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Purchase price for acquisition of assets and rights

'

'

'

$4,600,000

'

'

$1,100,000

'

$2,500,000

'

$6,700,000

'

$1,200,000

'

'

$400,000

'

'

'

'

Acquisition date of assets and rights

'

'

'

'

'

'

30-Jul-13

'

'

30-Aug-13

'

31-Aug-14

'

'

'

'

'

31-Oct-12

'

'

Cash paid for assets purchased

'

'

'

4,300,000

'

'

900,000

400,000

2,100,000

'

5,100,000

'

'

'

1,200,000

300,000

'

'

'

'

Cash paid for manufacturing and distribution rights

'

'

'

'

300,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Intangible assets

'

'

'

2,800,000

'

300,000

'

'

1,100,000

'

1,794,000

'

800,000

'

'

276,000

'

'

135,000

3,000

Goodwill

'

'

'

1,800,000

'

600,000

'

'

700,000

'

'

'

'

'

'

100,000

'

'

'

'

Maximum goodwill deductible for tax purposes

'

'

'

'15 years

'

'15 years

'

'

'15 years

'

'

'

'

'

'

'15 years

'

'

'

'

Weighted average useful life

'7 years 9 months 18 days

'

'12 years

'

'

'

'5 years 8 months 12 days

'

'6 years 8 months 12 days

'

'

'

'5 years

'

'

'

'5 years

'

'5 years

'2 years

Balance payable to Clinical Instruments

'

'

'

'

'

'

200,000

'

'

'

1,400,000

'

'

'

'

100,000

'

'

'

'

Inventory

'

'

'

'

'

'

200,000

'

'

'

'

'

400,000

'

'

26,000

'

'

'

'

Acquisition-related contingent consideration

'

'

'

'

'

'

'

'

1,400,000

'

'

'

'

'

'

'

'

'

'

'

Tangible assets

'

'

'

'

'

'

'

'

800,000

'

'

'

'

'

'

'

'

'

'

'

Assumed liabilities

'

'

'

'

'

'

'

200,000

100,000

200,000

1,731,000

'

'

'

'

'

'

'

'

'

Fair value of contingent consideration

100,000

'

'

'

'

'

'

100,000

'

100,000

'

'

'

'

'

'

'

'

'

'

Adjustment to tangible asset acquired

'

'

'

'

'

'

'

'

'

'

'

'

'

200,000

'

'

'

'

'

'

Business acquisition, assumed debt

'

'

'

'

'

'

'

'

'

'

1,100,000

'

'

'

'

'

'

'

'

'

Goodwill

17,441,000

15,031,000

'

'

'

'

'

'

'

'

2,482,000

'

'

'

'

80,000

'

'

'

'

Deferred tax assets acquired

'

'

'

'

'

'

'

'

'

'

$2,400,000

'

'

'

'

'

'

'

'

'

Acquisition_and_Divestitures_S

Acquisition and Divestitures - Schedule of Recognized Identified Assets Acquired and Liabilities Assumed (Detail) (USD $)	Sep. 30, 2014	Dec. 31, 2013	Aug. 31, 2014	Sep. 30, 2014
In Thousands, unless otherwise specified			Xenotis Pty Ltd [Member]	AngioScope [Member]
Business Acquisition [Line Items]	'	'	'	'
Current assets	'	'	$2,110	'
Inventory	'	'	'	26
Property and equipment, net	'	'	2,054	38
Intangible assets	'	'	1,794	276
Goodwill	17,441	15,031	2,482	80
Total assets acquired	'	'	8,440	420
Total liabilities assumed	'	'	-1,731	'
Purchase price	'	'	$6,709	$420

Acquisition_and_Divestitures_A1

Acquisition and Divestitures - Acquired Intangible Assets and Related Estimated Useful Lives (Detail) (USD $)	9 Months Ended		1 Months Ended					1 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Aug. 31, 2014	Aug. 31, 2014	Aug. 31, 2014	Aug. 31, 2014	Aug. 31, 2014	Sep. 30, 2014	Sep. 30, 2014	Sep. 30, 2014	Sep. 30, 2014	Sep. 30, 2014
		Xenotis Pty Ltd [Member]	Xenotis Pty Ltd [Member]	Xenotis Pty Ltd [Member]	Xenotis Pty Ltd [Member]	Xenotis Pty Ltd [Member]	AngioScope [Member]	AngioScope [Member]	AngioScope [Member]	AngioScope [Member]	AngioScope [Member]
			Non-compete Agreement [Member]	Trade Name [Member]	Technology [Member]	Customer Relationships [Member]		Non-compete Agreement [Member]	Trade Name [Member]	Technology [Member]	Customer Relationships [Member]
Business Acquisition [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Allocated fair value	'	$1,794	$135	$142	$1,465	$52	$276	$3	$28	$163	$82
Weighted average useful life	'7 years 9 months 18 days	'	'5 years	'7 years	'7 years	'7 years	'	'2 years	'7 years	'7 years	'9 years

Goodwill_and_Other_Intangibles2

Goodwill and Other Intangibles - Schedule of Goodwill (Detail) (USD $)	9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014
Goodwill and Intangible Assets Disclosure [Abstract]	'
Balance at beginning of year	$15,031
Additions for acquisitions	2,562
Effects of currency exchange	-152
Balance at September 30, 2014	$17,441

Goodwill_and_Other_Intangibles3

Goodwill and Other Intangibles - Components of Identifiable Intangible Assets (Detail) (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Finite-Lived Intangible Assets [Line Items]	'	'
Gross Carrying Value	$13,570	$10,899
Accumulated Amortization	5,935	4,755
Net Carrying Value of Intangible Assets	7,635	6,144
Patents [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Gross Carrying Value	7,225	5,679
Accumulated Amortization	2,589	1,932
Net Carrying Value of Intangible Assets	4,636	3,747
Trademarks and Technology Licenses [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Gross Carrying Value	1,575	1,414
Accumulated Amortization	1,044	935
Net Carrying Value of Intangible Assets	531	479
Customer Relationships [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Gross Carrying Value	3,675	2,835
Accumulated Amortization	1,683	1,441
Net Carrying Value of Intangible Assets	1,992	1,394
Other Intangible Assets [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Gross Carrying Value	1,095	971
Accumulated Amortization	619	447
Net Carrying Value of Intangible Assets	$476	$524

Goodwill_and_Other_Intangibles4

Goodwill and Other Intangibles - Additional Information (Detail) (USD $)	3 Months Ended	9 Months Ended
In Millions, unless otherwise specified	Jun. 30, 2014	Sep. 30, 2014
Finite-Lived Intangible Assets [Line Items]	'	'
Weighted-average amortization period for intangibles	'	'7 years 9 months 18 days
Impairment charge related to trademark and technology upon termination	$0.20	'
Additional charge to cost of sales	$0.30	'
Maximum [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Intangible assets useful lives	'	'13 years
Minimum [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Intangible assets useful lives	'	'1 year

Goodwill_and_Other_Intangibles5

Goodwill and Other Intangibles - Amortization Expense Included in General and Administrative Expense (Detail) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Goodwill and Intangible Assets Disclosure [Abstract]	'	'	'	'
Amortization expense	$359	$323	$1,098	$857

Goodwill_and_Other_Intangibles6

Goodwill and Other Intangibles - Estimated Amortization Expense for Remainder of 2014 and Each of Five Succeeding Fiscal Years (Detail) (USD $)	Sep. 30, 2014
In Thousands, unless otherwise specified
Goodwill and Intangible Assets Disclosure [Abstract]	'
Amortization expense, Remainder of Fiscal Year 2014	$435
Amortization expense, Fiscal Year 2015	434
Amortization expense, Fiscal Year 2016	1,294
Amortization expense, Fiscal Year 2017	1,049
Amortization expense, Fiscal Year 2018	934
Amortization expense, Fiscal Year 2019	$773

Accrued_Expenses_Accrued_Expen

Accrued Expenses - Accrued Expenses (Detail) (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Payables and Accruals [Abstract]	'	'
Compensation and related taxes	$4,519	$4,710
Income and other taxes	1,606	885
Professional fees	508	428
Restructuring charges	48	'
Other	1,894	1,970
Total	$8,670	$7,993

Restructuring_Additional_Infor

Restructuring - Additional Information (Detail) (USD $)	1 Months Ended		3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Apr. 30, 2014	Feb. 28, 2014	Jun. 30, 2014	Mar. 31, 2014	Sep. 30, 2014
	Employees
Commitments and Contingencies Disclosure [Abstract]	'	'	'	'	'
Percentage of reduction in workforce	'	10.00%	'	'	'
Severance costs	'	'	$100	$400	$473
Employees terminated	7	'	'	'	'

Restructuring_Components_of_Re

Restructuring - Components of Restructuring Charges (Detail) (USD $)	3 Months Ended			9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Sep. 30, 2014
Reorganizations [Abstract]	'	'	'	'
Severance	'	$100	$400	$473
Other	8	'	'	27
Total	$8	'	'	$500

Restructuring_Activity_Related

Restructuring - Activity Related to Accrued Restructuring Costs (Detail) (USD $)	3 Months Ended	9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2014
Reorganizations [Abstract]	'	'
Balance at beginning of year	'	$0
Plus: Current year restructuring costs	8	500
Less: Payment of employee severance costs	'	425
Payment of other expenses	8	27
Balance at end of period	$48	$48

Commitments_and_Contingencies_

Commitments and Contingencies - Additional Information (Detail) (USD $)	9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2014
Commitments and Contingencies Disclosure [Abstract]	'
Commitments to purchase inventory	$3.10
Purchase commitments inventory expire year	'2016

Segment_and_EnterpriseWide_Dis2

Segment and Enterprise-Wide Disclosures - Additional Information (Detail)	9 Months Ended
	Sep. 30, 2014
	Segment
Segment Reporting [Abstract]	'
Number of operating segments	1

Segment_and_EnterpriseWide_Dis3

Segment and Enterprise-Wide Disclosures - Net Sales to Unaffiliated Customers by Geography (Detail) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Segment Reporting Information [Line Items]	'	'	'	'
Net sales	$17,501	$15,300	$52,416	$46,633
United States [Member]	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'
Net sales	10,605	9,506	31,221	28,820
Germany [Member]	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'
Net sales	1,789	1,805	5,551	5,166
Japan [Member]	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'
Net sales	581	609	1,704	1,779
Other Countries [Member]	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'
Net sales	$4,526	$3,380	$13,940	$10,868

Sharebased_Compensation_Shareb

Share-based Compensation - Share-based Compensation Expense (Detail) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Schedule of Trading Securities and Other Trading Assets [Line Items]	'	'	'	'
Total share-based compensation	$439	$412	$982	$967
Stock Option Awards [Member]	'	'	'	'
Schedule of Trading Securities and Other Trading Assets [Line Items]	'	'	'	'
Total share-based compensation	294	252	687	596
Restricted Stock Units [Member]	'	'	'	'
Schedule of Trading Securities and Other Trading Assets [Line Items]	'	'	'	'
Total share-based compensation	$145	$160	$295	$371

Sharebased_Compensation_Fair_V

Share-based Compensation - Fair Values of Employee Stock Options for Option Grants Issued Valuation Assumptions Using Black-Scholes Option Model (Detail) (USD $)	9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
Equity [Abstract]	'	'
Dividend yield	1.80%	1.80%
Volatility	45.20%	57.90%
Risk-free interest rate	2.00%	1.60%
Weighted average expected option term (in years)	'5 years 6 months	'5 years 7 months 6 days
Weighted average fair value per share of options granted	$2.81	$3

Sharebased_Compensation_Additi

Share-based Compensation - Additional Information (Detail) (USD $)	9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
Schedule Of Summary Of Restricted Stock Unit Activity [Line Items]	'	'
Issue of common stock	175,000	255,000
Restricted Stock Units [Member]	'	'
Schedule Of Summary Of Restricted Stock Unit Activity [Line Items]	'	'
Weighted average fair value of restricted stock units	7.87	6.67

Net_Income_per_Share_Computati

Net Income per Share - Computation of Basic and Diluted Net Income per Share (Detail) (USD $)	3 Months Ended		9 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Basic:	'	'	'	'
Net income available for common stockholders	$934	$721	$1,999	$2,456
Weighted average shares outstanding	17,348	15,339	16,358	15,262
Basic earnings per share	$0.05	$0.05	$0.12	$0.16
Diluted:	'	'	'	'
Net income available for common stockholders	$934	$721	$1,999	$2,456
Weighted-average shares outstanding	17,348	15,339	16,358	15,262
Common stock equivalents, if diluted	361	441	414	445
Shares used in computing diluted earnings per common share	17,709	15,780	16,772	15,707
Diluted earnings per share	$0.05	$0.05	$0.12	$0.16
Shares excluded in computing diluted earnings per share as those shares would be anti-dilutive	356	395	228	438

Stockholders_Equity_Additional

Stockholders' Equity - Additional Information (Detail) (USD $)	0 Months Ended	9 Months Ended			3 Months Ended
In Millions, except Share data, unless otherwise specified	Jun. 04, 2014	Sep. 30, 2014	Jun. 04, 2014	Dec. 31, 2013	Mar. 31, 2013	Nov. 30, 2011	Jun. 14, 2012	Jun. 14, 2012
					Common Stock [Member]	Common Stock [Member]	Maximum [Member]	Minimum [Member]
Business Acquisition, Equity Interests Issued or Issuable [Line Items]	'	'	'	'	'	'	'	'
Common stock, shares authorized	'	37,000,000	'	37,000,000	'	'	100,000,000	37,000,000
Preferred stock, shares authorized	'	3,000,000	'	3,000,000	'	'	5,000,000	3,000,000
Common stock, share issued	'	18,778,436	1,644,500	16,959,330	'	'	'	'
Common stock, par value	'	$0.01	$0.01	$0.01	'	'	'	'
Share price, per share	'	'	$7	'	'	'	'	'
Net proceeds from issuance of shares	$10.50	'	'	'	'	'	'	'
Cash dividend on common stock per share	'	$0.04	'	'	'	'	'	'
Dividend payment date	'	4-Dec-14	'	'	'	'	'	'
Dividends payment amount	'	0.6	'	'	'	'	'	'
Dividend record date	'	20-Nov-14	'	'	'	'	'	'
Repurchase of common stock	'	'	'	'	'	10	'	'
Repurchase of common stock, number of shares	'	'	'	'	15,000	'	'	'
Repurchase of common stock, value	'	'	'	'	$0.10	'	'	'

Stockholders_Equity_Dividend_A

Stockholders' Equity - Dividend Activity (Detail) (USD $)

3 Months Ended

9 Months Ended

1 Months Ended

9 Months Ended

1 Months Ended

9 Months Ended

1 Months Ended

9 Months Ended

1 Months Ended

9 Months Ended

1 Months Ended

9 Months Ended

1 Months Ended

9 Months Ended

1 Months Ended

9 Months Ended

In Thousands, except Per Share data, unless otherwise specified

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Feb. 28, 2011

Sep. 30, 2014

Apr. 03, 2014

Feb. 28, 2011

Sep. 30, 2014

Jun. 05, 2014

Feb. 28, 2011

Sep. 30, 2014

Sep. 04, 2014

Feb. 28, 2011

Sep. 30, 2013

Apr. 03, 2013

Feb. 28, 2011

Sep. 30, 2013

Jun. 05, 2013

Feb. 28, 2011

Sep. 30, 2013

Sep. 04, 2013

Feb. 28, 2011

Sep. 30, 2013

Dec. 04, 2013

Installment 1 FY 2014 [Member]

Installment 1 FY 2014 [Member]

Installment 1 FY 2014 [Member]

Installment 2 FY 2014 [Member]

Installment 2 FY 2014 [Member]

Installment 2 FY 2014 [Member]

Installment 3 FY 2014 [Member]

Installment 3 FY 2014 [Member]

Installment 3 FY 2014 [Member]

Installment 1 FY 2013 [Member]

Installment 1 FY 2013 [Member]

Installment 1 FY 2013 [Member]

Installment 2 FY 2013 [Member]

Installment 2 FY 2013 [Member]

Installment 2 FY 2013 [Member]

Installment 3 FY 2013 [Member]

Installment 3 FY 2013 [Member]

Installment 3 FY 2013 [Member]

Installment 4 FY 2013 [Member]

Installment 4 FY 2013 [Member]

Installment 4 FY 2013 [Member]

Dividends Payable [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Record Date

'

'

20-Nov-14

'

'

20-Mar-14

'

'

22-May-14

'

'

21-Aug-14

'

'

20-Mar-13

'

'

22-May-13

'

'

21-Aug-13

'

'

20-Nov-13

'

Payment Date

'

'

4-Dec-14

'

'

3-Apr-14

'

'

5-Jun-14

'

'

4-Sep-14

'

'

3-Apr-13

'

'

5-Jun-13

'

'

4-Sep-13

'

'

4-Dec-13

'

Per Share Amount

$0.04

$0.03

$0.11

$0.09

$0.04

'

'

$0.04

'

'

$0.04

'

'

$0.03

'

'

$0.03

'

'

$0.03

'

'

$0.03

'

'

Dividend Payment

'

'

'

'

'

'

$546

'

'

$547

'

'

$607

'

'

$457

'

'

$457

'

'

$460

'

'

$464

Supplemental_Cash_Flow_Informa2

Supplemental Cash Flow Information - Supplemental Cash Flow Information (Detail) (USD $)	9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013
Supplemental Cash Flow Elements [Abstract]	'	'
Cash paid for income taxes, net	$1,276	$755
Common stock repurchased for RSU tax withholdings	$211	$246

Fair_Value_Measurements_Additi

Fair Value Measurements - Additional Information (Detail) (USD $)	Sep. 30, 2014
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'
Fair value of contingent consideration	$100,000
Level 1 [Member]	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'
Cash equivalents in money market fund	12,000,000
Recurring [Member] | Level 2 [Member]	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'
Assets measured at fair value	$0

Fair_Value_Measurements_Rollfo

Fair Value Measurements - Rollforward of the Fair Value as Determined by Level 3 (Detail) (USD $)	9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014
Fair Value Disclosures [Abstract]	'
Beginning balance	$99
Additions (reductions)	'
Change in fair value included in earnings	138
Ending Balance	$237

Accumulated_Other_Comprehensiv2

Accumulated Other Comprehensive Loss - Summary of Accumulated Other Comprehensive Loss (Detail) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Equity [Abstract]	'	'	'	'
Beginning balance	'	'	($253)	($433)
Other comprehensive income (loss) before reclassifications	'	'	-1,375	90
Amounts reclassified from accumulated other comprehensive loss	'	'	'	'
Net current period other comprehensive income (loss)	-1,378	310	-1,375	90
Ending Balance	($1,628)	($343)	($1,628)	($343)